National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedBlanco C, Okuda M, Wang S
Testing the drug substitution switching-addictions hypothesis. A prospective study in a nationally representative sample.
The researchers tested whether remission from a substance use disorder (SUD) would increase the probability of new onset of an SUD. In a national sample of 34,653 adults, they found that contrary to a common clinical perception, remission from an SUD decreases rather than increases the risk of onset of another SUD.
AHRQ-funded; HS021112
Citation: Blanco C, Okuda M, Wang S .
Testing the drug substitution switching-addictions hypothesis. A prospective study in a nationally representative sample.
JAMA Psychiatry. 2014 Nov;71(11):1246-53. doi: 10.1001/jamapsychiatry.2014.1206..
Keywords: Comparative Effectiveness, Substance Abuse, Behavioral Health
Hartung DM, McCarty D, Fu R
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
The authors evaluated cost and utilization outcomes between extended-release naltrexone (XR-NTX) and other pharmacotherapies for treatment of alcohol and opioid dependence. They found that alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone, with healthcare utilization and costs being generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.
AHRQ-funded; HS019456.
Citation: Hartung DM, McCarty D, Fu R .
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
J Subst Abuse Treat 2014 Aug;47(2):113-21. doi: 10.1016/j.jsat.2014.03.007.
.
.
Keywords: Alcohol Use, Comparative Effectiveness, Medication, Opioids, Substance Abuse